These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL. Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015 [TBL] [Abstract][Full Text] [Related]
25. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871 [TBL] [Abstract][Full Text] [Related]
26. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. Parkhurst MR; DePan C; Riley JP; Rosenberg SA; Shu S J Immunol; 2003 May; 170(10):5317-25. PubMed ID: 12734382 [TBL] [Abstract][Full Text] [Related]
27. Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations. Meng Z; Wang Y; Zhang G; Ke Y; Yan Y; Wu L; Huang Q; Zeng G; Wang Y; Ying H; Jiao S J Immunother; 2011 Sep; 34(7):525-34. PubMed ID: 21760531 [TBL] [Abstract][Full Text] [Related]
29. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). Loftus DJ; Castelli C; Clay TM; Squarcina P; Marincola FM; Nishimura MI; Parmiani G; Appella E; Rivoltini L J Exp Med; 1996 Aug; 184(2):647-57. PubMed ID: 8760818 [TBL] [Abstract][Full Text] [Related]
30. Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes. Adamina M; Bolli M; Albo F; Cavazza A; Zajac P; Padovan E; Schumacher R; Reschner A; Feder C; Marti WR; Oertli D; Heberer M; Spagnoli GC Br J Cancer; 2004 Jan; 90(1):263-9. PubMed ID: 14710238 [TBL] [Abstract][Full Text] [Related]
31. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Jäger E; Maeurer M; Höhn H; Karbach J; Jäger D; Zidianakis Z; Bakhshandeh-Bath A; Orth J; Neukirch C; Necker A; Reichert TE; Knuth A Int J Cancer; 2000 May; 86(4):538-47. PubMed ID: 10797269 [TBL] [Abstract][Full Text] [Related]
32. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones. Kirkin AF; thor Straten P; Hansen MR; Barfoed A; Dzhandzhugazyan KN; Zeuthen J Cancer Immunol Immunother; 1999 Aug; 48(5):239-46. PubMed ID: 10478640 [TBL] [Abstract][Full Text] [Related]
33. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Palmowski M; Salio M; Dunbar RP; Cerundolo V Immunol Rev; 2002 Oct; 188():155-63. PubMed ID: 12445289 [TBL] [Abstract][Full Text] [Related]
34. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430 [TBL] [Abstract][Full Text] [Related]
35. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Lopes L; Fletcher K; Ikeda Y; Collins M Cancer Immunol Immunother; 2006 Aug; 55(8):1011-6. PubMed ID: 16311731 [TBL] [Abstract][Full Text] [Related]
36. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy. von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403 [TBL] [Abstract][Full Text] [Related]
37. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. D'Souza S; Rimoldi D; Líenard D; Lejeune F; Cerottini JC; Romero P Int J Cancer; 1998 Dec; 78(6):699-706. PubMed ID: 9833762 [TBL] [Abstract][Full Text] [Related]
38. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Romero P; Valmori D; Pittet MJ; Zippelius A; Rimoldi D; Lévy F; Dutoit V; Ayyoub M; Rubio-Godoy V; Michielin O; Guillaume P; Batard P; Luescher IF; Lejeune F; Liénard D; Rufer N; Dietrich PY; Speiser DE; Cerottini JC Immunol Rev; 2002 Oct; 188():81-96. PubMed ID: 12445283 [TBL] [Abstract][Full Text] [Related]
39. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro. Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322 [TBL] [Abstract][Full Text] [Related]
40. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. Skoberne M; Yewdall A; Bahjat KS; Godefroy E; Lauer P; Lemmens E; Liu W; Luckett W; Leong M; Dubensky TW; Brockstedt DG; Bhardwaj N J Clin Invest; 2008 Dec; 118(12):3990-4001. PubMed ID: 19033668 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]